Targets › ACVR1
3 programs from 3 companies in 25 trials: 15 Phase 2, 9 Phase 1, 1 Phase 3; Oncology, Hematology, Immunology; next expected readout Dec 2026.
Bone morphogenetic protein (BMP) type I receptor that is involved in a wide variety of biological processes, including bone, heart, cartilage, nervous, and reproductive system development and regulation. As a type I receptor, forms heterotetrameric receptor complexes with the type II receptors AMHR2, ACVR2A or ACVR2B. Upon binding of ligands such as BMP7 or GDF2/BMP9 to the heteromeric complexes, type II receptors…. (UniProt, Q04771)
Open in Phaseline: the race on ACVR1, likelihood bands and readouts
| Company | Drug | Targets | Highest phase | Conditions | Next expected readout |
|---|---|---|---|---|---|
| Swedish Orphan Biovitrum | Pacritinib Tyrosine-protein kinase JAK2 inhibitor; Tyrosine-protein kinase receptor FLT3 inhibitor; Activin receptor type-1 inhibitor | JAK2, FLT3, ACVR1, IRAK1 | Phase 3 | Primary Myelofibrosis; VEXAS; Myelofibrosis; Acute Myeloid Leukemia … | Dec 2026 |
| GSK | Momelotinib Tyrosine-protein kinase JAK1 inhibitor; Tyrosine-protein kinase JAK2 inhibitor; Activin receptor type-1 inhibitor | JAK1, JAK2, ACVR1 | Phase 2 | Primary Myelofibrosis; Myelodysplastic Syndromes; VEXAS Syndome; Myeloid Leukemia … | Dec 2026 |
| Theradex | Pacritinib Tyrosine-protein kinase JAK2 inhibitor; Tyrosine-protein kinase receptor FLT3 inhibitor; Activin receptor type-1 inhibitor | JAK2, FLT3, ACVR1, IRAK1 | Phase 2 | Leukemia, Myelomonocytic, Chronic | Jul 2028 |
Primary Myelofibrosis (4) Myelofibrosis (3) Myelodysplastic Syndromes (2) VEXAS Syndome (1) Myeloid Leukemia (1) VEXAS (1) Acute Myeloid Leukemia (1) T-Cell Neoplasm (1) Myelofibrosis,MF (1) Waldenström Macroglobulinemia (1) Accelerated Phase Myeloproliferative Neoplasm (1) Prostate Cancer (1)
small molecule (3)
Programs group each company's trials by drug; targets and mechanisms come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood is in the app.